Boenisch Sandra reported grant involving 20,000 derivative units of ANAVEX LIFE SCIENCES CORP. at $0.00 for $0 on Sep 24, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
PFO & Treasurer
PFO & Treasurer
Filed Sep 28, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
20,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
20,000Direct
Trade date
Sep 24, 2026Grant
Filed
Sep 28, 2026, 9:36 PM ET5-day reporting delay
Accession
0001731122-26-001296Code A · Transaction 230708
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 24, 2026Grant25,000$0.00$0Trade 230709
2 transaction rows in this filing. Joint filers share the same rows.

AVXL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
AVXL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −32%30d −45%90d180d1y

Footnotes in full

F1: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.